Xihu Innovation Investment

Xihu Innovation Investment (西湖创新投资) is a fund that appears in elsewhere's corpus primarily through its investment activity in biotech during 2021–2022. It led the near-100-million-yuan Pre-A+ round in CASI (凯思凯迪), a Shanghai-based biopharma startup focused on nuclear receptor and GPCR-targeting drugs for metabolic and inflammatory diseases, with that round closing in February 2022 . The fund also backed Aikai Biotech (艾凯生物), a Suzhou cell-therapy company that completed three funding rounds totaling over 300 million yuan within its first year of founding in March 2021, alongside investors including 5Y Capital and Lianxin Capital . Elsewhere's corpus does not contain additional profile material on the fund's background, team, or broader strategy beyond these deal participations.